Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.

about

Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.

Item

http://www.wikidata.org/entity/Q55482080

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Sustained SREBP-1-dependent li ...... ance to BRAF-targeted therapy.

@en

Sustained SREBP-1-dependent li ...... ance to BRAF-targeted therapy.

@nl

type

Item

label

Sustained SREBP-1-dependent li ...... ance to BRAF-targeted therapy.

@en

Sustained SREBP-1-dependent li ...... ance to BRAF-targeted therapy.

@nl

prefLabel

Sustained SREBP-1-dependent li ...... ance to BRAF-targeted therapy.

@en

Sustained SREBP-1-dependent li ...... ance to BRAF-targeted therapy.

@nl

P1476

Sustained SREBP-1-dependent li ...... ance to BRAF-targeted therapy.

@en

P2093

Aljosja Rogiers

http://www.w3.org/2001/XMLSchema#string

Etienne Waelkens

http://www.w3.org/2001/XMLSchema#string

Florian Rambow

http://www.w3.org/2001/XMLSchema#string

Francesca Bosisio

http://www.w3.org/2001/XMLSchema#string

Frank Vanderhoydonc

http://www.w3.org/2001/XMLSchema#string

Joao A G Duarte

http://www.w3.org/2001/XMLSchema#string

Jonas Dehairs

http://www.w3.org/2001/XMLSchema#string

Joost Van den Oord

http://www.w3.org/2001/XMLSchema#string

Kathleen Van den Eynde

http://www.w3.org/2001/XMLSchema#string

Kris Nys

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Lipid metabolic reprogramming in cancer cells

Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

P2888

s41467-018-04664-0

P304

2500

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41467-018-04664-0

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Christophe Marine

P577

2018-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1105054480

http://www.w3.org/2001/XMLSchema#string

P698

29950559

http://www.w3.org/2001/XMLSchema#string

P932

6021375

http://www.w3.org/2001/XMLSchema#string